FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
wasiiiigton,	D.C.	20349

STATEMENT	ΛE	CHANGES	INI DE	NEELCIAL	OWNEDCHI	D
STATEMENT	UГ	CHANGES		NEFICIAL	OWNERSHI	

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average b	urden							
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Mosca Alison						2. Issuer Name and Ticker or Trading Symbol Clene Inc. [CLNN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>iviosca</u>	Alison				Ľ	Ciche me. [CLINI]						X	Director		10% Owner						
					— З.	3. Date of Earliest Transaction (Month/Day/Year)								Officer (d	give title		Other (s	pecify			
(Last)	(F	irst)	(Middle)		06/16/2023								below)	-		below)	·				
6550 SO	UTH MILL	ROCK DRIVE			-													· · · · ·			
SUITE (4.	If Am	endment, D	oate of	Original Fi	ied (Month/Da	ay/Year)		6. Ind Line)	6. Individual or Joint/Group Filing (Check Applicable						
SUITE	300													X	1 '						
					-	Form filed by One Reporting Person Form filed by More than One Reporting											- 1				
(Street)						Form f Persor										d by More than One Reporting			.iiig		
SALT L	AKE U	Т	84121		-					_											
CITY	Ī		•		R	Rule 10b5-1(c) Transaction Indication															
					- _	_															
(City)	(S	State)	(Zip)			Che	eck this box t affirmative d	to indica Jefense	ate that a tra	nsac of Rul	tion was n le 10h5-1(nade pur	suant to	a contract, n 10	instruction o	r written pla	an that i	s intended to	satisfy		
							dillimative d	10101130	Conditions	, real	010001(0). 000 11	ion deno								
		Ta	able I - No	n-Der	ivativ	ve S	ecurities	s Acc	quired, [Disp	osed (of, or	Bene	ficially	Owned						
1. Title of	Security (Inst	tr. 3)			sactio	n	2A. Deeme		3.		4. Secui								7. Nature of		
				Date (Month	n/Day/Y	ear)	Execution Date, r) if any		Transacti Code (Ins		Dispose	ed Of (D)	(Instr. 3	3, 4 and 5)) Securities Beneficially		Form: Direct (D) or Indirect		Indirect Beneficial Ownership		
				`	II/Day/ reary		(Month/Da	y/Year)							Owned Fo	ollowing (I) (str. 4)			
										v	Amount		(A) or	Price	Reported Transaction	on(s)		- [(Instr. 4)		
									Code	<u> </u>	Amount	`	(D)	FIICE	(Instr. 3 ar	nd 4)					
	0 1			0.04		/2022								0.000				By			
Common	Stock			06/1	/16/2023				P		2,394	2,394,375 A		\$0.8	3,238,375		I		LLC ⁽¹⁾		
									-		_	_			1						
Common Stock															39,4	1 76		D			
Common Stock															3 006	670		T I	By LP ⁽²⁾		
Common Stock											3,006,670			1	by Lr · ·						
Common Stock													1,459,945 I By								
Common Stock															1,435	,343		1	trust ⁽³⁾		
			Table II -				curities . Ils, warr								wned						
4 7711					-	,			-	_					0.000.00			40	44 11.1		
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Da	ıte, 4	Tansac	tion	5. Number Derivative		6. Date Exe Expiration I		bie and			nount of lerlying	8. Price of Derivative	9. Numbe		10. Ownership	11. Nature of Indirect		
Security (Instr. 3)	or Exercise Price of	(Month/Day/Year)	if any			ıstr.	Securities Acquired (A)		(Month/Day	/Year			erivative Security nstr. 3 and 4)		Security (Instr. 5)	Securities Beneficially		Form: Direct (D)	Beneficial Ownership		
(msu. s)	Derivative				''		or Dispose	eď				(iiisti. 3 anu 4)			(msu. J)	Owned	d	or Indirect	(Instr. 4)		
	Security					of (D) (Instr. 3, 4 and 5)									Following Reported		(I) (Instr. 4)				
				\vdash	 		Amount or				ion(s)										
					ode	v	(A)		Date Exercisable		cpiration ate	Title	Nu	nber of ares		(Instr. 4)					
				+	Joue		(~)	(5)	LACIOISADIC	+		11110	-	41.03					+		
Warrants (Right to	\$1.5	06/16/2023			A		2,394,375		06/16/2023		(5)	Commo		394,375	(4)	2,394,3	375	D			
buy)	****	30, 10, 2023					_,55 ,,57 5		55,10,2020			Stock	[,,,,,,,		_,554,					
Warrants								\Box		Т											
(Right to buy)	\$1.1	06/16/2023			A		2,394,375		06/16/2023		(6)	Commo		894,375	(4)	2,394,3	375	D			

Explanation of Responses:

- 1. The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest. Please note that Kensington Clene 2021, LLC had been incorrectly referred to in prior form 4s for Ms. Mosca as Kensington Clene, LLC; there is no such legal entity, only Kensington Clene 2021, LLC.
- 2. The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P., for which she does not have a pecuniary or profits interest.
- 3. The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust.
- 4. The price for each Unit is \$0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
- 5. Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of \$1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration approval of a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

6. Kensington Clene 2021, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 2,394,375 shares of Common Stock of Clene Inc. at an exercise price of \$1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

Remarks:

/s/ Jerry Miraglia POA

06/20/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.